What was recalled
This page synthesizes the tryptophan-to-niacin endogenous synthesis framework and its implications for commercial pet food formulation. Niacin (vitamin B3) is required for biosynthesis of nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+), the central electron-carrier cofactors for hundreds of oxidation-reduction reactions across cellular metabolism. NAD+ is required for glycolysis, citric acid cycle function, fatty acid oxidation, ethanol metabolism, and DNA repair through poly-ADP-ribose polymerase (PARP). NADP+ is required for fatty acid synthesis, cholesterol synthesis, nucleotide synthesis, and antioxidant defense through glutathione reductase regeneration. Mammals can satisfy niacin requirement through dietary intake of niacin itself (as nicotinic acid or nicotinamide, both standard pet food premix forms covered in our niacin source controversy page) or through endogenous synthesis from tryptophan via the kynurenine pathway.
The kynurenine pathway is a multi-enzyme cascade that converts tryptophan to either quinolinic acid (the niacin precursor branch) or picolinic acid (an alternative branch with separate metabolic fate). The pathway proceeds: tryptophan → N-formylkynurenine (via IDO or TDO) → kynurenine → 3-hydroxykynurenine (via KMO) → 3-hydroxyanthranilic acid (via kynureninase) → 2-amino-3-carboxymuconic semialdehyde (via 3-HAO). At this branch point, two competing enzymes determine fate: QPRT (quinolinic acid phosphoribosyltransferase) commits the substrate toward niacin synthesis through quinolinic acid; picolinic carboxylase commits the substrate toward picolinic acid through decarboxylation. In humans and dogs, the QPRT branch dominates at typical metabolic flux, producing approximately 60:1 tryptophan-to-niacin conversion ratio in humans (and a similar though less precisely characterized ratio in dogs). In cats, picolinic carboxylase activity is constitutively very high, shunting substrate away from QPRT and producing essentially zero net niacin synthesis from tryptophan.
The regulatory consequence is reflected in AAFCO Nutrient Profiles. AAFCO feline niacin minimum is approximately 4x canine: 60 mg/kg dry matter for feline maintenance versus 13.6 mg/kg dry matter for canine adult maintenance. The feline minimum is set to support niacin requirement entirely from dietary intake without conversion contribution. Canine minimum is set lower because tryptophan-to-niacin conversion contributes to total niacin equivalent supply, particularly in formulations with adequate tryptophan content. The niacin equivalent (NE) framework used in human dietary reference intake formulation (and informally in some veterinary nutrition contexts for dogs) calculates total niacin supply as dietary niacin plus tryptophan / 60. The NE framework does not apply to cats — feline tryptophan intake makes essentially zero niacin contribution.
Why it was recalled
The structural concerns have three layers. Layer one — high feline picolinic carboxylase activity is constitutive, not regulatory: the feline 4x niacin requirement relative to canine is not a temporary or context-dependent phenomenon but a fixed species-physiology difference in kynurenine pathway branch-point activity. Picolinic carboxylase activity in feline liver is constitutively several-fold higher than in canine or human liver, and the activity does not down-regulate in response to niacin deficiency or tryptophan abundance. The consequence is that cats cannot compensate for marginal dietary niacin intake by increasing tryptophan intake — the conversion pathway does not function regardless of substrate availability.
Layer two — the niacin equivalent (NE) framework that applies to humans and dogs does not apply to cats: human and canine dietary reference intake formulation can use the NE framework (total niacin = dietary niacin + tryptophan / 60) to assess sufficiency. Pet food formulators working with canine formulations can reasonably credit tryptophan content toward total niacin equivalent supply, allowing modest dietary niacin minimums to be adequate when paired with high-tryptophan animal-protein-anchored formulations. Pet food formulators working with feline formulations must satisfy the entire niacin requirement through direct dietary niacin (nicotinic acid or nicotinamide), regardless of tryptophan content. Plant-protein-heavy or tryptophan-rich feline formulations gain no niacin equivalent advantage from the tryptophan content — a structural framework that occasionally surfaces in formulation-margin failure events involving feline diets.
Layer three — the kynurenine pathway has independent regulatory implications for tryptophan availability: the kynurenine pathway also produces several intermediates with independent biological activity, including kynurenic acid (a glutamate receptor antagonist with neurological effects), quinolinic acid (a neurotoxic NMDA receptor agonist at elevated concentrations), and several immunomodulatory metabolites. In contexts of immune activation, infection, or inflammation, IDO is upregulated and tryptophan flux through the kynurenine pathway increases, depleting tryptophan availability for serotonin synthesis and protein synthesis. The pathway therefore has cross-system implications for behavior, neurological function, and immune balance independent of the niacin synthesis branch. In feline diets, where the kynurenine pathway does not contribute to niacin supply, the pathway still produces kynurenine intermediates with biological activity — an underappreciated framework in feline behavioral nutrition.
Health risks for your pet
Clinical niacin deficiency in dogs and cats produces a syndrome historically called "black tongue" or canine pellagra (in dogs) and a similar but less specifically named syndrome in cats. The presentation includes oral ulceration with thick saliva and foul odor, glossitis with dark discoloration of the tongue, weight loss, diarrhea with bloody stool in severe cases, and dermatitis in chronic cases. The syndrome is exacerbated when both niacin and tryptophan are inadequate (in dogs), and in cats requires only inadequate niacin since tryptophan provides no conversion contribution. Clinical niacin deficiency is essentially absent from commercial-fed dogs and cats because AAFCO compliance plus typical formulation overage covers requirements with substantial margin.
The pet-food-specific concern is the structural framework gap in feline plant-protein-heavy formulations. A pet food formulator working from human or canine NE-framework intuition might credit tryptophan-rich feline ingredients (egg, animal protein hydrolysates, certain plant proteins) toward total niacin equivalent supply, and underestimate the dietary niacin requirement that must be satisfied from direct supplementation. The structural margin in feline formulations is therefore narrower than in canine formulations, and formulation-margin failure events involving feline niacin have surfaced occasionally in the historical pet food recall record (though less prominently than the thiamine outbreak cluster covered on our thiamine deficiency outbreak history page).
What to do if you bought affected product
Pet owners can interpret tryptophan and niacin pet food framework appropriately through several practical approaches: (1) understand that cats are obligate dietary niacin consumers — the kynurenine pathway tryptophan-to-niacin conversion that supports human and canine niacin sufficiency does not function in cats because of constitutively high picolinic carboxylase activity; (2) do not assume tryptophan-rich feline diets provide niacin equivalent supply — the niacin equivalent (NE) framework that applies to humans and dogs does not apply to cats; feline formulations must satisfy the entire niacin requirement through direct dietary niacin (nicotinic acid or nicotinamide); (3) recognize that AAFCO feline niacin minimum is approximately 4x canine (60 mg/kg dry matter for feline maintenance vs 13.6 mg/kg for canine) — this differential reflects the species-physiology difference in conversion pathway and is not a formulation choice; (4) watch for clinical signs of niacin deficiency in commercially-fed pets — oral ulceration, glossitis with darkened tongue, weight loss, diarrhea, dermatitis; these signs are rare in commercial-fed pets but warrant veterinary evaluation if they appear; (5) consider tryptophan adequacy for feline serotonin and behavioral support — even though tryptophan provides no niacin equivalent in cats, tryptophan is still the essential amino acid precursor for serotonin synthesis and protein synthesis, and feline behavioral nutrition formulations occasionally include elevated tryptophan content for serotonin support; (6) treat the species-physiology framework as a transparency-quality signal — brands explicitly disclosing feline niacin compliance margin and dietary niacin form (nicotinic acid vs nicotinamide) typically reflect better overall feline-formulation transparency than brands using generic niacin labeling.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate tryptophan-niacin equivalent framework at the brand level per our published methodology, since the framework is most relevant for formulation-margin assessment rather than consumer-visible product evaluation. Future rubric extension under consideration: feline formulations with explicit niacin compliance documentation and source-form disclosure (nicotinic acid vs nicotinamide, both covered in our niacin source controversy page) would warrant favorable scoring weight as transparency signal. For now, our recommendation: assume AAFCO-compliant commercial cat food meets feline niacin requirements through direct dietary niacin supplementation, do not interpret tryptophan-rich feline ingredients as contributing to niacin equivalent supply, and treat the species-physiology framework as foundational background for evaluating feline nutritional adequacy claims.